Tesamorelin: the FDA-approved GHRH analog explained
A synthetic version of growth hormone-releasing hormone — and one of the few peptides in this category with a real FDA-approved indication, even if the compounded version is not.
TL;DR
- Tesamorelin is a synthetic GHRH analog (a peptide that signals the pituitary to release growth hormone).
- The branded version, Egrifta, is FDA-approved for one specific HIV-related indication; the compounded version is not FDA-approved.
- It is most often discussed for its effects on visceral fat — the deep abdominal fat around organs.
What it is
Tesamorelin is a 44-amino-acid peptide. It is a synthetic version of growth hormone-releasing hormone (GHRH) — the natural signal the brain sends to the pituitary gland to release growth hormone. The molecule is modified at one end so it stays intact in the bloodstream longer than the natural hormone (Falutz et al., New England Journal of Medicine, 2007).
The brand name is Egrifta. The FDA approved Egrifta in 2010 for one specific use: reducing excess abdominal fat in people with HIV-associated lipodystrophy (FDA prescribing information for Egrifta, 2014). Compounded tesamorelin used in other settings is not FDA-approved.
How it works
Think of the pituitary as a faucet for growth hormone. Tesamorelin is a longer-lasting version of the natural signal that opens the faucet.
When tesamorelin is injected, it binds to GHRH receptors on the pituitary. That triggers a pulse of growth hormone release into the bloodstream. The growth hormone then signals the liver to make IGF-1 (in plain English: a downstream growth factor that does much of the work growth hormone is known for). Animal and human research has connected this pathway to changes in visceral fat (Falutz et al., 2007).
Who asks about it
People usually arrive at tesamorelin after reading about it as a visceral fat option. The follow-up question is the same one we hear with most peptides: what is it actually doing, and where does the FDA stand on it?
What the research says
The largest published trials are in HIV-associated lipodystrophy. In those studies, treated patients showed reductions in visceral fat compared with placebo (Falutz et al., 2007). The data outside that population — for example, healthy adults using tesamorelin for healthy-aging body composition — is much thinner.
What to know before considering it
Tesamorelin requires a prescription and a licensed clinician evaluation. Side effects in the published literature include injection-site reactions, joint discomfort, and changes in glucose handling. Compounded tesamorelin is not FDA-approved.
The Halftime POV
Tesamorelin sits in a useful spot in the peptide map: a real FDA approval, a clean mechanism story, and a body of research that is mostly tied to one specific population. We treat that history honestly rather than borrowing the FDA approval to imply outcomes outside the population it was studied in.
Related reading:
- Tesamorelin and visceral fat research
- Sermorelin explained: the GHRH analog
- CJC-1295: what this modified GHRH peptide is
FAQ
Q: What is tesamorelin? A: Tesamorelin is a synthetic GHRH analog (in plain English: a small peptide modeled on the body’s growth hormone-releasing hormone). It signals the pituitary to release growth hormone.
Q: Is tesamorelin FDA-approved? A: Tesamorelin under the brand name Egrifta is FDA-approved for one specific use: reducing excess abdominal fat in people with HIV-associated lipodystrophy. The compounded version used in other settings is not FDA-approved.
Q: How is tesamorelin different from sermorelin? A: Both are GHRH analogs. Tesamorelin is structurally modified to last longer in the bloodstream than the natural hormone. Sermorelin is a closer match to the natural sequence and clears faster.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV-infected patients with abdominal fat accumulation. New England Journal of Medicine, 2007.
- Egrifta (tesamorelin for injection) prescribing information. U.S. Food and Drug Administration, 2014.
